欢迎来到OAJRC平台！

期刊栏目

投稿

审稿

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据：

当前位置：国际医药研究前沿 > 2024年 8卷 (2)期

Open Access Article

International Medical Research Frontier. 2024; 8: (2) ; 22-29 ; DOI: 10.12208/j.imrf.20240016.

A review of the mechanism of action and novel targets of antidepressants
抗抑郁药物作用机制与新型靶点研究综述

作者： 杨娜 *

广东医科大学广东东莞

*通讯作者：杨娜,单位：广东医科大学广东东莞；

发布时间: 2024-12-31 总浏览量: 195

PDF 全文下载引用本文

摘要

本文综述了抗抑郁药物的作用机制，并探讨了新型靶点的研究进展。首先概述了传统抗抑郁药物如三环类、选择性5-羟色胺再摄取抑制剂（SSRIs）和单胺氧化酶抑制剂（MAOIs）的作用原理。随后重点介绍了新型靶点的研究，包括谷氨酸系统、神经营养因子、神经炎症、肠道微生物群以及表观遗传学等领域的最新发现。这些新型靶点为未来抗抑郁药物的开发提供了新的方向，有助于提高治疗效果并减少副作用。最后强调了多靶点策略在抗抑郁治疗中的潜力，以及个性化医疗在抑郁症治疗中的重要性。

关键词： 抗抑郁药物；作用机制；新型靶点；神经营养因子

Abstract

This paper reviews the mechanism of action of antidepressants and explores the research progress of novel targets. First, the mechanism of action of traditional antidepressants such as tricyclics, selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs) is outlined. Then, the research on novel targets is focused on, including the latest discoveries in the fields of glutamate system, neurotrophic factors, neuroinflammation, intestinal microbiota, and epigenetics. These novel targets provide new directions for the development of future antidepressants, which will help improve the therapeutic effect and reduce side effects. Finally, the potential of multi-target strategy in antidepressant treatment and the importance of personalized medicine in the treatment of depression are emphasized.

Key words： Antidepressants; Mechanism of action; Novel targets; Neurotrophic factors

参考文献 References

[1] Protti M, Mandrioli R, Marasca C, et al. New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others[J]. Medicinal Research Reviews, 2020, 40(5): 1794-1832.

[2] Sheffler Z M, Patel P, Abdijadid S. Antidepressants[M]// StatPearls [Internet]. StatPearls Publishing, 2023.

[3] Casarotto P C, Girych M, Fred S M, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors[J]. Cell, 2021, 184(5): 1299-1313. e19.

[4] Yuan Z, Chen Z, Xue M, et al. Application of antidepressants in depression: a systematic review and meta-analysis[J]. Journal of Clinical Neuroscience, 2020, 80: 169-181.

[5] Moncrieff J. Persistent adverse effects of antidepressants[J]. Epidemiology and Psychiatric Sciences, 2020, 29: e56.

[6] Moraczewski J, Awosika A O, Aedma K K. Tricyclic antidepressants[M]//StatPearls [Internet]. StatPearls Publishing, 2023.

[7] Castillo-Zacarías C, Barocio M E, Hidalgo-Vázquez E, et al. Antidepressant drugs as emerging contaminants: Occurrence in urban and non-urban waters and analytical methods for their detection[J]. Science of the Total Environment, 2021, 757: 143722.

[8] Kornhuber J, Gulbins E. New molecular targets for antidepressant drugs[J]. Pharmaceuticals, 2021, 14(9): 894.

[9] Gonda X, Dome P, Neill J C, et al. Novel antidepressant drugs: Beyond monoamine targets[J]. CNS spectrums, 2023, 28(1): 6-15.

[10] 周其冈.发现新一代快速起效抗抑郁药物靶点[J].前沿科学, 2023, 17(1):78-81.

[11] 赵弘毅,丁伟健,冯飞翔,等.抑郁症易感基因和抗抑郁药物靶点相关神经细胞类型及相互作用网络分析[J].生物信息学, 2024, 22(2):124-133.

[12] 贾雨、刘子超、王美玉、徐莉英.以 NMDAR 为靶点的抗抑郁药物的研究进展[J].中国药物化学杂志, 2020(8):7. DOI:CNKI:SUN:ZGYH.0.2020-08-011.

[13] 徐祥清,常山泉.以5-羟色胺2A受体为靶点的抗抑郁药研究进展[J].医药导报, 2023, 42(7):1061-1066.

[14] 汪洋,郭飞,夏明钰.抑郁症药物治疗的研究进展[J].山东化工, 2024, 53(13):156-160,164.

[15] 陈涛,皮超,陈婧林,等.抗抑郁药物的分子机制及未来研究方向[J].中国药理学与毒理学杂志, 2023(7).

[16] 张书懂,周媛,张志芳,等.抗抑郁药物不同治疗时期抑郁症患者脑功能影像的变化[J].中华行为医学与脑科学杂志, 2022, 31(4):7.DOI:10.3760/cma.j.cn371468-2021110-00642.

[17] 黄鹏,汤卓红,王星,等.miRNA-139-5p在制备预防或治疗抑郁症靶向药物中的应用:CN202210066968.9 [P]. CN114515340A[2025-06-22].

[18] 凌芳,柯德宏,罗强,等.吲哚类抗抑郁药物的研究进展[J].化学试剂, 2023, 45(3):37-46.

[19] 夏平友.基于快速抗抑郁作用机制研究[J].中文科技期刊数据库（全文版）医药卫生, 2022(7):292-297.

[20] 任霞.度洛西汀联合TAAR1/5-HT1A双激动剂SEP-363856治疗抑郁症的研究[D].江苏海洋大学,2022.

[21] 陈慧丽.谷氨酰胺酶1在抑郁症中的作用研究[D].同济大学,2022.

[22] 朱颖奇.盐酸苯环壬酯的抗抑郁作用及其机制研究[D].陕西师范大学,2020.

引用本文

杨娜, 抗抑郁药物作用机制与新型靶点研究综述[J]. 国际医药研究前沿, 2024; 8: (2) : 22-29.

入驻平台

回到首页

搜索文章: